Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02727803
Title Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

chronic myeloid leukemia

Hodgkin's lymphoma

myelodysplastic/myeloproliferative neoplasm

acute leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

chronic myelomonocytic leukemia

chronic lymphocytic leukemia

acute lymphoblastic leukemia

acute myeloid leukemia

CLL/SLL

multiple myeloma

Therapies

anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan

anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab

anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells

Age Groups: child | adult | senior
Covered Countries USA

Additional content available in CKB BOOST